ebola virus

N-(1-benzyl-4-piperidyl)adamantane-1-carboxamide inhibiting the entry of Ebola virus in host cells by binding to the surface glycoprotein, the compound inhibited the Ebola virus with EC50 of 3.9 μM.

EBOV-IN-1 is an adamantane dipeptide piperazine inhibitor against Ebola virus (EBOV) that inhibits EBOV infection and suppresses pseudotypic EBOV infection.

2-Phenylethyl Acetate is an Ebola virus inhibitor and can be used in biochemical experiments and drug synthesis.

FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.

FGI-106 tetrahydrochloride demonstrates potent inhibitory activity across a broad spectrum of viruses, including those causing hemorrhagic fevers such as Ebola, Rift Valley, and Dengue Fever, with half-maximal effective concentrations (EC50s) of 100 nM, 800 nM, and 400-900 nM, respectively. Additionally, it effectively inhibits non-hemorrhagic fever viruses, notably HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively, indicating its broad-spectrum antiviral potential.

IHVR-19029 is an effective endoplasmic reticulum (ER) α-glucosidases I and II inhibitor (IC50: 0.48 μM for ER a-glucosidase I). IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Ebola virus, Dengue virus, and Rift

Pyronaridine tetraphosphate is an orally active, mannitol-containing inhibitor of DNA topoisomerase 2 and erythrocyte cytokine with antimalarial and antitumour activity.Pyronaridine tetraphosphate treats P. falciparum and Echinococcus granulosus infections. Pyronaridine tetraphosphate treats P. falciparum and Echinococcus granulosus infections and attenuates Ebola virus transmission.

U18666A is a cell-permeable drug and is a cholesterol synthesis and transport inhibitor. It inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus.

Antiviralagent 59 (compound 58) is a selective antiviral agent with drug-like properties, capable of inhibiting a broad spectrum of filoviruses. It demonstrates low off-target activity and inhibitory effects against replicative forms of Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV).

EBOV-IN-10 is an orally active inhibitor of the Ebola virus (EBOV) with an EC50 value of 0.19 μM.

BIBX 1382 Dihydrochloride prevents Lassa and Ebola virus glycoprotein-dependent cells from entering the body. It can be used as a tool to understand conserved virus-host interactions and suggests that host cell kinases may be targets for broad-spectrum th

Anti-virus agent 1 (compound 4i), a phosphoramidate prodrug of GS-5734, exhibits potent antiviral efficacy and is primarily utilized in coronavirus and Ebola virus (EBOV) research.

Cephaeline hydrochloride, a phenolic alkaloid found in Indian Ipecac, effectively inhibits the infection of viruses ZIKV and EBOV.

As-358 exhibits inhibitory effects against the Ebola virus (IC50 = 47.5 μM) and the Marburg virus (IC50 = 3.7 μM) [1].

As-358 (hydrochloride) shows well in vivo safety as well as inhibits Ebola virus and Marburg virus with IC 50 values of 9.1 μM and 18.1 μM [1].

EBOV-GP-IN-1 (Compound 28) is a potent inhibitor of Ebola virus entry, targeting the Ebola virus envelope glycoprotein (EBOV-GP) with an IC50 of 0.05 μM.

EBOV-IN-C31 is a novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties.

Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. Efficacy of remdesivir against Ebola virus has been demonstrated. Remdesivir inhibits SARS-CoV-2 replication, reduces viral load, and exerts protective effects in SARS-CoV-2 infected animals. Remdesivir also reduces the pathological process, alleviates mild symptoms, and improves pulmonary lesions in SARS-CoV-2-infecetd animals. Remdesivir has been used as a compassionate drug for treating COVID-19 patients. *******WARNING****** Our product remdesivir is a pure chemical solid powder which is only for laboratory research use, NOT FOR HUMAN OR PATIENT USE

CLR01 is a molecular tweezer. CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. CLR01 inhibits Ebola and Zika virus infection. CLR01 Stabilizes a Disordered Protein-Protein Interface. CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.

Thiocarbazate, also known as CID16725315, is an inhibitor of human cathepsin L. Inhibition of cathepsin L thus holds promise for therapeutic intervention for both SARS-CoV and Ebola virus infection. With respect to the development of antiviral agents, inhibitors of human cathepsin L are not subject to resistance because of rapid mutations of the viral genome. Cathepsin L is therefore an attractive target for drug development.

Oxocarbazate, also known as CID23631927, is an inhibitor of human cathepsin L. In the cathepsin L inhibition assay, The oxocarbazate caused a time-dependent 17-fold drop in IC50 from 6.9 nM (no preincubation) to 0.4 nM (4-h preincubation). Slowly reversible inhibition was demonstrated in a dilution assay. CID23631927 demonstrate activity in blocking both SARS-CoV (IC50 = 273 nM) and Ebola virus (IC50 = 193 nM) entry into human embryonic. CID 23631927 was a subnanomolar, slow-binding, reversible inhibitor of human cathepsin L that blocked SARS-CoV and Ebola pseudotype virus entry in human cells. Inhibition of cathepsin L thus holds promise for therapeutic intervention for both SARS-CoV and Ebola virus infection.

Eritoran, a Toll-like receptor 4 (TLR4) antagonist, effectively protects mice from lethal infections caused by viruses such as the Ebola virus (EBOV) and Marburg virus (MARV). By decreasing granulocytosis levels, Eritoran may reduce the severity of cytokine storms, thereby inhibiting the pathogenesis of filovirus infections [1].

Larcaviximab (c4G7-N) is a chimeric monoclonal antibody of the IgG1 kappa class, specifically targeting the Ebola virus glycoprotein [1].

Odesivimab (REGN-3471) is a human monoclonal antibody targeting the Zaire strain of Ebola virus, with potential antiviral activity, used for research on Ebola virus infection.